Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
$449.16
-$0.58(-0.25%)
At close: 4:00 PM EST
$449.16
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$205.87 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.08M
Market Cap
$59.34B
Enterprise Value$62.68B
Total Cash (Recent Filing)$2.72B
Total Debt (Recent Filing)$2.77B
Price to Earnings (P/E)1868.4
Beta0.95
Next Earnings
Feb 12, 2026EPS Estimate
1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.84
Shares Outstanding132,113,820
10 Day Avg. Volume1,049,944
30 Day Avg. Volume1,081,522
Financial Highlights & Ratios
PEG Ratio2.84
Price to Book (P/B)447.73
Price to Sales (P/S)13.36
P/FCF Ratio-705.29
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue19.53
Enterprise Value/Gross Profit23.25
Enterprise Value/Ebitda336.00
Forecast
1Y Price Target
$504.24Price Target Upside12.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)2.26
Revenue Forecast (FY)$3.72B
Bulls Say, Bears Say
Bulls Say
Financial GuidanceAlnylam raised its 2025 total net product revenue guidance by $275 million, reflecting strong performance and growth expectations.
Market ExpansionAmvuttra is now being used at the ~170 target health systems securing broad access for ATTR-CM patients.
Revenue GrowthAmvuttra sales significantly exceeded expectations, contributing to higher net product revenue.
Bears Say
Government InvestigationThe stock is under pressure from disclosure of a subpoena related to government price reporting.
Sales DeclineOnpattro sales experienced a decline compared to previous quarters.
Stock PerformanceShares of Alnylam closed weak, down around 7%, following the quarterly print, likely due to lofty investor expectations for Amvuttra sales.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $205.87 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $59.34B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 88 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $0.561 by $1.279.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.28.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 132,113,820 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.84 in its last earnings report, beating expectations of $0.561. Following the earnings report the stock price went down -6.651%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$504.24 (12.26% Upside)
$504.24 (12.26% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 162.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.15%
12-Months-Change
Fundamentals
Return on Equity
32.73%
Trailing 12-Months
Asset Growth
15.38%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies based on RNA interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a leader in the RNAi therapeutics sector, aiming to treat a range of diseases by silencing specific genes. The company's core products include Onpattro (patisiran), which is approved for the treatment of hereditary transthyretin-mediated amyloidosis, and several other investigational therapies targeting various genetic disorders and conditions.
ALNY Company Deck
ALNY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in the TTR franchise and strong pipeline advancements, with increased financial guidance indicating confidence in future performance. However, challenges remain with decreased gross margins and increased expenses, along with ongoing pricing negotiations in Europe.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$504.24
▲(12.26% Upside)
Technical Analysis
Ownership Overview
0.42% Insiders
48.94% Mutual Funds
0.29% Other Institutional Investors
33.99% Public Companies and
Individual Investors